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Rac1, a member of the Rho family of GTPases, is a ubiquitous intracellular transducer protein that interacts with specific effectors (eg, p-21-activated kinase) to mediate a diverse array of cellular functions, including cytoskeleton remodeling, microtubule stability, gene transcription, and superoxide production. 1 Rac1 and related Rho GTPases regulate the formation, reorganization, and maturation of neuronal dendrites, 2, 3 indicating a key role for these proteins in modulating cellular processes underlying normative brain functions. Conversely, Rac1 dysfunction has been implicated in mental retardation syndromes 3, 4 and neurodegenerative diseases, including Parkinson's disease 5 and Alzheimer's disease (AD).
pathologic hallmark lesions, there is a reduction in cholinergic basal forebrain (CBF) projection neurons located within the septal diagonal band complex and the nucleus basalis of Meynert (NB) 10 -13 and a loss of choline acetyltransferase (ChAT; the synthetic enzyme for acetylcholine) in CBF hippocampal and cortical target fields in late AD. 14 -18 These cholinergic deficits correlate with cognitive decline and disease severity in AD. 19 -21 NFTs are found in CBF neurons in the brains of people who died with a clinical diagnosis of AD [22] [23] [24] and mild cognitive impairment (MCI), 24 ,25 a putative prodromal AD stage. However, whether Rac1 expression is associated with the onset of NFT pathology within CBF neurons during disease progression remains an open question.
Interestingly, CBF neurons depend on nerve growth factor (NGF) for their survival, and in vitro studies have shown that the proapoptotic pan-neurotrophin receptor, p75
NTR , activates Rac1 in a NGF-dependent manner, which may initiate cytoskeletal abnormalities or apoptotic signaling in AD. 26 Moreover, data derived from in vivo and in vitro investigations show that A␤ interacts with Rac1 to induce cytoskeletal changes related to NFT formation 27, 28 and that RhoA proteins abnormally accumulate in NFT-bearing neurons in AD. 6 Taken together, these observations suggest that dysregulation of the Rho GTPase Rac1 is associated with neuronal cytoskeletal alterations in AD.
A decade ago, a new isoform of Rac termed Rac1b was identified in breast and colon cancers. 29, 30 Rac1b is a self-activated splicing variant of Rac1 that displays a 19-amino acid (aa) insert from exon 3b that creates a novel effector-binding site absence in Rac1. 29, 31 The presence of these additional 19 aa altered the structure and activity of Rac1b, 32, 33 rendering it a constitutively active variant of Rac1. 34 Thus, Rac1b overactivation may play a prominent role in Rac1-related cellular neurodegeneration. Recently, a transcriptomic profiling technology developed by Exonhit 35 was used to compare alternative RNA splicing events present in frontal cortex from AD (Braak stage VI) and age-matched healthy controls, which identified splicing alterations occurring in Rac1 in AD brain. 36 Moreover, in a preliminary report we found Rac1b immunoreactivity within NFT-bearing p75 NTR -positive NB neurons in end-stage AD. 37 However, the potential role of Rac1b in the development of NFT pathology within NB neurons during the progression of AD has not been explored. In the present study, we examined the spatiotemporal nature of Rac1b expression with respect to tau epitopes underlying NFT formation within p75 NTRpositive NB neurons in postmortem tissue harvested from people who died with a clinical diagnosis of no cognitive impairment (NCI), MCI, or AD. Furthermore, we compared gene expression profiles of Rac1b-immunopositive (Rac1b ϩ ) and Rac1b-immunonegative (Rac1b Ϫ ) NB neurons by laser capture microdissection coupled with custom-designed microarray analysis to identify targets of potential Rac1b-mediated mechanisms of neurodegeneration in AD.
Materials and Methods

Alternative RNA Splicing for Rac1 in AD Brain and Other Tissues
Expression profiling technology developed by ExonHit (Paris, France) 35 was used to compare alternative RNA splicing events present in Rac1 within frozen brain tissues accrued from frontal cortex (Brodmann area 9) from Braak stage VI AD and nondemented healthy controls both 70 years old. RT-PCR technology determined Rac1b expression levels in different tissues, including brain. 29 The primers used were F1, 5=-ATGCAGGCCATCAAGT-GTGTGG-3=; R1, 5=-TGGCATTGAGTGCGAAGGC-3=; and F2, 5=-AAAGACAAGCCGATTGCCG-3=. A discrete band representing a 492-bp amplicon that corresponds to the expected size of the Rac1b amplicon was detected in the brain samples. The amplicon was cloned into Topo TA cloning vector (Invitrogen, Paris, France) and sequenced with SP6 and T7 primers to confirm the sequence identity of the Rac1b amplification product.
Generation and Specificity of a Rac1b Antibody
Generation of the Rac1b Antibody
An anti-Rac1b serum (SG-4088) was produced by Sigma-Genosys (Sigma-Aldrich, St. Louis, MO) according to their standard immunization protocol by coupling the peptide VGETYGKDITSRGKDKPIAC from AD frontal cortex to keyhole limpet hemocyanin. Serum was then affinity-purified on a Sepharose column with the use of the immunogen as bait.
Specificity of the Rac1b Antibody
Ten nanograms of either recombinant Rac1 or Rac1b [glutathione S-transferase (GST)-tagged; 50 kDa each; Cytoskeleton, Denver, CO] was separated by electrophoresis in a 12% SDS-PAGE system and transferred to Hybond-C membranes (Amersham Biosciences, Paris, France). After transfer, membranes were blocked with 5% nonfat milk in 0.1% PBS/0.1% Tween-20 and incubated overnight with the primary rabbit anti-Rac1b antibody SG-4088 at a 1:5000 dilution, or with a mouse monoclonal anti-Rac1 antibody ARC03 (1:5000; Cytoskeleton, Denver, CO). Immunologic complexes were developed with an anti-rabbit or an anti-mouse peroxidase antibody (1:5000; Jackson Laboratories, Paris, France) followed by enhanced chemiluminescence (Amersham Biosciences, Paris, France).
Cell Culture and Immunoblot Analysis
Myc (alias c-myc)-tagged Rac1b was cloned into the NIT tet off-expression vector, 38 kindly provided by Dr. Fred H. Gage (The Salk Institute, La Jolla, CA). NIH3T3 cells (LGC PromoChem, Molsheim, France) were grown in high-glucose Dulbecco's modified Eagle's medium plus Glutamax supplemented with 10% newborn serum and antibiotics. NIH3T3 cells were transiently transfected with NIT-Rac1b in the presence or absence of various doses of doxycycline (Sigma-Aldrich). Forty-eight hours after transfection, cells were lysed and 7.5 g of protein was separated on a 12% SDS-PAGE gel and transferred to Hybond-C membranes (Amersham Biosciences). After transfer, membranes were blocked with 5% nonfat milk in 0.1% PBS/0.1% Tween-20 and incubated overnight with the anti-Rac1b antibody at 1:5000, allowing for the detection of both endogenous and Myc-tagged Rac1b. The membrane was then stripped at 55°C for 20 minutes and reprobed with an anti-Myc monoclonal antibody at 1:750 (Tebu, Le Perray en Yvelines, France). Immunologic complexes were shown with anti-rabbit or an anti-mouse IgG (1:5000; Jackson Laboratories) followed by chemiluminescence (Amersham Biosciences).
Cell Culture and Immunocytochemistry
Human embryonic kidney (HEK) 293 cells were maintained in modified Eagle's medium plus Earle's salt supplemented with 10% fetal bovine serum, 2 mmol/L L-glutamine (Sigma-Aldrich), nonessential amino acids, and antibiotics. 2 ϫ 10 5 HEK293 cells/well were seeded in 6-well plates for 24 hours and transiently transfected with the Myc-tagged Rac1b expression vector or empty vector with the use of Lipofectamine Plus (Invitrogen). Fortyeight hours after transfection, cells were fixed with 4% paraformaldehyde in PBS, permeabilized with 0.1% Triton X-100, saturated in 5% nonfat milk/1% bovine serum albumin, and processed for Rac1b fluorescence immunohistochemistry (SG-4088, 1:500).
Brain Tissue Accrual
The Human Investigations Committee of Rush University Medical Center and Northwestern University School of Medicine approved tissue usage for this study. Postmortem tissue containing the CBF neurons of the NB was harvested from 28 participants in the Religious Orders Study, 39 -42 a longitudinal clinical pathologic study of aging and AD in older Catholic nuns, priests, and brothers conducted by Rush University Medical Center (Chicago, IL). Subjects were clinically characterized within a year of death as having NCI (n ϭ 12), MCI (n ϭ 8, 6 with nonamnestic MCI and 2 with amnestic MCI), and mild AD (n ϭ 7). All MCI and AD cases were evaluated clinically and pathologically as described previously. [43] [44] [45] [46] [47] [48] [49] Cortical tissue was also harvested from four NCI, MCI, and AD cases to test the specificity of the Rac1b antibody.
In addition, brain tissue from 8 cases neuropathologically characterized as severe (end-stage) AD, based on Braak stage, were accessed from the Rush Alzheimer's Disease Brain Bank. A summary of the clinical and neuropathologic demographics of the cases examined in this study is shown in Table 1 . To test for disease specificity of Rac1b immunolabeling within CBF neurons of the NB, we examined tissue harvested from two other tauopathies: Lewy Body disease (LBD; n ϭ 4) and frontotemporal dementia (FTD; n ϭ 3) (see Table 2 ) accrued from Northwestern University School of Medicine (Chicago, IL). Consensus criteria incorporated into the procedures of the Uniform Data Set of the NIA Alzheimer's Disease Centers program 50, 51 were used for the clinical diagnosis of FTD. Pathologic diagnosis of frontotemporal lobar degeneration (FTLD) and specification of its variants were rendered according to the published consensus criteria set forth by the Consortium for FTLD. 52 All tissue samples were fixed at autopsy in 4% paraformaldehyde, cryoprotected, and cut at 40 m on a freezing sliding microtome for immunohistochemical and gene expression analyses as reported previously. 43, 44, 53 Antibody Characterization Antibodies used to detect cholinergic neurons of the NB included a mouse monoclonal antibody generated against p75 NTR (epitope aa 1 to 160) derived from A875 melanoma cells (clone NGFR5; LabVision, Fremont, CA), which is an excellent marker of CBF neurons in the human healthy aged and AD brain 54, 55 and a goat polyclonal antiserum to ChAT (Millipore, Billerica, MA), which specifically marks cholinergic neurons in human brain. 56 -58 These antibodies were used in colocalization experiments with Rac1b and tau-specific epitope markers for NFTs. Antibody specificity of each cholinergic marker was reported by their manufacturers.
The tau antibodies used in this study included Alz50, a mouse monoclonal antibody (gift from Dr. P. Davies, Albert Einstein School of Medicine, Bronx, NY), which shows an early-stage conformational tau epitope (aa 5 to 15, 312 to 322) and marks neurons undergoing early degenerative events associated with NFT formation, 59 -61 AT180 mouse monoclonal antibody (ThermoFisher, Pittsburgh, PA), which detects tau phosphorylation at the threonine 231 site, an early event in the disassembly of tau, 62, 63 and the AT8 mouse monoclonal antibody (ThermoFisher), which marks tau phosphorylation at both serine 202 and threonine 205 sites. 64 The specificity of the tau antibodies has been reported by numerous investigators 59 -64 and by their manufacturers.
Immunoblot and Immunohistochemistry
Cortical samples from NCI (n ϭ 4) and severe AD (n ϭ 4) were processed for Western blot analysis as reported previously. 65 Briefly, tissue was sonicated in ice-cold homogenization buffer (20 mmol/L Tris, 1 mmol/L EGTA, 1 mmol/L EDTA, 10% sucrose, pH 7.4) containing protease inhibitors, and protein concentration of S1 fraction was determined by the Bradford method (Bio-Rad, Hercules, CA). Sample proteins (48 g/sample) were separated by SDS-PAGE (7.5% acrylamide) and transferred electrophoretically to polyvinylidene fluoride membranes (Immobilon P; Millipore). Membrane was incubated overnight with rabbit anti-Rac1b antiserum (our SG-4088; 1:1000) and developed with a horseradish peroxidase-conjugated goat anti-rabbit IgG (1:5000; Bio-Rad). Immunoreactive proteins were visualized by enhanced chemiluminescence (Amersham Biosciences) on a Kodak Image Station 440CF (Eastman Kodak, Cincinnati, Ohio).
Floating sections containing the NB region of the basal forebrain extending from the decussation of the anterior commissure until its emergence from the temporal lobe, caudally, were dual immunolabeled for p75 NTR (1:15,000) and the polyclonal rabbit Rac1b-specific antibody (1: 1000) with the use of tissue sections from NCI, MCI, mild/moderate AD, severe AD, LBD, or FTD cases. Sections were washed several times in Tris-buffered saline (TBS) before incubation with 0.1 mol/L sodium periodate (to inhibit endogenous peroxidase activity) in a TBS solution for 20 minutes. After several rinses in a solution containing 0.25% Triton X-100 in TBS, the tissue was placed in a blocking solution containing TBS with 0.25% Triton X-100 and 3% goat serum for 1 hour. Sections were subsequently incubated in rabbit anti-Rac1b antibody for 24 hours in a medium containing TBS 0.25% Triton X-100 and 1% goat normal serum. After washes with 1% goat normal serum in TBS, sections were incubated with biotinylated goat anti-rabbit (Vector Laboratories, Burlingame, CA) for 1 hour. After several washes in TBS the tissue was incubated for 60 minutes with an avidin-biotin complex (1:500; "Elite Kit"; Vector Laboratories). Tissue was rinsed in 0.2 mol/L sodium acetate, 1.0 mol/L imidazole buffer (pH 7.4), and developed in an acetate-imidazole buffer containing 2.5% nickel sulfate, 0.05% 3,3=-diaminobenzidine tetrahydrochochloride (Sigma-Aldrich) and 0.0015% H 2 O 2 . The reaction was terminated with an acetate-imidazole buffer solution. Subsequently, and after several washes in TBS, sections were incubated with anti-p75 NTR antibody for 24 hours in a medium containing TBS 0.25% Triton X-100 and 1% goat normal serum, and then incubated with biotinylated goat anti-mouse (Vector Laboratories) and visualized with the chromogen 3,3=-diaminobenzidine tetrahydrochochloride (brown) without nickel intensification following the above protocol. This dual staining resulted in an easily identifiable two-colored profile: dark blue/black for Rac1b and brown for p75 NTRpositive profiles. 54 Bright-field images were acquired with Nikon microphot microscope (Nikon, Melville, NY). Additional sections were either double or triple immunofluorescence labeled with the use of antibodies directed against Rac1b (1:100; SG-4088), ChAT (1:100), the early conformational tau antibody Alz50 (1:4000), and the tau phosphorylation antibodies AT180 (1: 300) and AT8 (1: 100). Fluorescence signals were shown with Cy3-, Cy2-, and Cy5-conjugated anti-mouse, rabbit, and goat IgGs (Jackson Immunoresearch, West Grove, PA), depending on the primary antibody. Double and triple immunofluorescence images were acquired and analyzed with a Zeiss Axioplan 2 (Zeiss, Thorndale, NY) and an Olympus confocal microscope equipped with FluoroView 4.3 software (Olympus, Center Valley, PA), respectively. Omission of primary antibodies resulted in a lack of immunoreactivity in tissue sections. To test the specificity of Rac1b antiserum the antibody was preabsorbed against purified Rac1b protein (0.1 mg/mL), followed by immunostaining of NB tissue with the above protocol. Furthermore, to test for the possible cross-reactivity between the tau antibodies and Rac1b, AT8 (1:1000) and Alz50 (1: 10,000) were preabsorbed with Rac1b protein (0.1 mg/ mL) overnight, followed by our standard immunostaining protocols. Preabsorption with the Rac1b protein did not prevent AT8 or Alz50 immunoreactivity.
Cell Distribution and Quantitation
The distribution of NB neurons single-and doublestained for Rac1b and p75 NTR receptor were charted with Neurolucida 8 (MicroBrightField Inc., Williston, VT) with the aid of Nikon Optiphot-2 microscope. Counts of single p75 NTR and double Rac1b/p75 NTR -immunoreactive (ir) cholinergic NB neurons were performed manually at magnification of ϫ40, and fiduciary landmarks were used to prevent repeat counting of neurons. The number of sections counted per case ranged from 6 to 11. Stereologic counting procedures were not used because the total number of neurons per region was not a requirement and the tissue was not prepared for unbiased counting. The results are presented as the percentage of Rac1b/ p75 NTR -immunopositive total neurons rather than absolute numbers of cell counts.
Single-Cell Gene Expression Analysis
Immunolabeled p75
NTR -positive NB neurons (n ϭ 140) from NCI cases (n ϭ 6) and immunolabeled p75 NTR and double-labeled Rac1b/p75 NTR NB neurons (n ϭ 260) from severe AD cases (n ϭ 7) were accessed by laser capture microdissection (Arcturus XT; Applied Biosystems). Because dual Rac1b
NTR CBF labeling was negligible in the MCI cases, gene expression comparisons were not performed. The amplification of mRNA from individual neurons was performed with terminal continuation RNA amplification methodology as previously described. 39 -42,53 Terminal continuation RNA amplification is a linear amplification process that preserves the original quantitative relationships among the transcripts. 39, 53, 66, 67 Hybridization probes were synthesized by in vitro transcription with the use of 33 P incorporation in 40 mmol/L Tris (pH 7.5); 6 mmol/L MgCl 2 ; 10 mmol/L NaCl; 2 mmol/L spermidine; 2.5 mmol/L DTT; 125 mol/L ATP, GTP, and CTP; 2.5 mol/L cold UTP; 20 U of RNase inhibitor; 2 kU of T7 RNA polymerase (Epicenter, Madison, WI); and 120 Ci of 33 P-UTP (PerkinElmer, Boston, MA). 68 The labeling reaction was performed at 37°C for 4 hours. Radiolabeled terminal continuation RNA probes were hybridized to custom-designed microarrays without further purification.
Custom-Designed Microarray Platforms
Array platforms consist of 1 g of linearized cDNA purified from plasmid preparations adhered to high-density nitrocellulose (Hybond XL; GE Healthcare, Piscataway, NJ) with the use of an arrayer robot (VersArray; BioRad). 39, 68, 69 Each cDNA and/or EST is verified by sequence analysis and restriction digestion. Approximately 576 cDNAs/ESTs are used on the array platform (see Supplemental Table S1 at http://ajp.amjpathol.org). Arrays were hybridized for 24 hours, washed with serial dilutions of saline sodium citrate buffer, and then placed in a phosphor screen for 24 hours before development on a phosphor imager with ImageQuant 5.2 software (GE Healthcare).
Hybridization signal intensity of the empty vector (pBS; double spotted on the array) identified background ac-tivity. 39, 53 Expression of terminal continuation-amplified RNA bound to each linearized cDNA was expressed as a ratio of the total hybridization signal intensity of the array (ie, global normalization), 39,69 -72 thereby minimizing variations because of differences in the specific activity of the probe and the absolute quantity of the probe present.
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Statistical Analysis
Demographic, clinical, and neuropathologic characteristics were compared across clinical diagnostic groups with one-way analysis of variance, Kruskal-Wallis or Fisher's exact test follow by Dunn's post hoc test for multiple comparisons (Sigma Stat 3.5; Systat Software, Inc., San Jose, CA). Cell count data were analyzed with KruskalWallis analysis of variance on ranks followed by Dunn's method for multiple comparisons, and correlations were performed with Spearman rank (Sigma Stat 3.5; Systat Software, Inc.). Single-cell gene array data were analyzed with GeneLinker 4.6 bioinformatics software with the use of a false discovery rate controlling procedure 68, 76 to reduce type I error (IOS, Kingston, ON). Levels of individual mRNAs were compared among NCI p75 NTR , AD p75 NTR , and AD Rac1b/p75 NTR with the use of one-way analysis of variance with post hoc Holm-Sidak testing for multiple comparisons (Sigma Stat 3.5, Systat Software, Inc.). Descriptive statistical level of significance was set at 0.05 (two-tailed).
Results
Subject Demographics
The portion of the study that evaluated Rac1b during the progression of AD included 36 subjects divided into four clinical diagnostic groups: 12 NCI, 8 MCI, 7 mild/moderate AD, and 8 severe AD ( 
Generation and Characterization of Rac1b Antibody
Expression profiling showed a dysregulation of the splicing of exon 3b of the Rac1 gene ( Figure 1A ), leading to overexpression of the Rac1b isoform in AD compared with age-matched control cortical brain tissue. Specifically, the Rac1b isoform displayed 19 aa insert from exon 3b, which is not present in Rac1 ( Figure 1A ). RT-PCR analyses showed Rac1b transcripts in specific normal body tissues (eg, heart, liver, placenta, and spleen) and cancer tissues [including MCF-7, a human breast adenocarcinoma cell line, and MDA MB 231 (breast, renal, and prostate cancer cells], whereas Rac1 transcripts were also detected in normal human frontal cortex, small intestine, and colon ( Figure 1B) . Interestingly, this alternative splicing of Rac1 was virtually undetectable within prefrontal cortex from human healthy controls ( Figure  1B ). Immunoblot analysis showed that the Rac1b antiserum (SG-4088) did not cross-react with Rac1, whereas the commercial anti-Rac1 antiserum (ARC03) recognized Rac1b protein (Figure 2A ). Rac1b cDNA was cloned into NIT tet off vector and transfected into NIH3T3 cells to test the specificity of the antibody (SG-4088) generated against the Rac1b isoform. Immunoblotting showed that the Rac1b antibody detected the expression of the Rac1b vector in NIH3T3 cells cultured in the presence of lower levels or the absence of doxycycline, as expected ( Figure 2B ). Notably, this antibody recognized endogenous Rac1b expression in NIH3T3 cells ( Figure 2B ). Likewise, HEK293 cells ( Figure 2C ) were immunopositive for Rac1b after 48 hours of transfection with a vector containing Rac1b cDNA ( Figure 2D ), whereas HEK293 cells transfected with empty vector were immunonegative (Figure 2, E and F). Moreover, immunoblotting showed that the Rac1b antiserum indicated the presence of Rac1b protein in the cortex of patients with AD, whereas no immunoreactivity was seen in the cortex of normal human controls ( Figure 3A) . These results indicated that the antiserum generated against Rac1b does not cross-react with Rac1 protein and thus specifically recognizes the Rac1b isoform in immunoblotting and immunocytochemical procedures.
General Characteristics of Rac1b Immunostaining in the NB
The immunohistochemical specificity of the Rac1b antiserum in the NB was determined by pre-absorption with the Rac1b protein, resulting in a lack of immunoreactive profiles within the NB ( Figure 3B ) compared with neurons dually immunostained for Rac1b and p75 NTR without preabsorption ( Figure 3C ). To examine the characteristics and distribution of Rac1b immunoreactivity in the NB during the progression of AD, tissue from each clinical group was double immunostained for Rac1b and p75 NTR . Although most of the Rac1b-ir neurons also displayed p75 NTR , not all p75 NTR co-expressed Rac1b ( Figure 3C ). Rac1b ϩ /p75 NTR -positive NB neurons were more frequent in mild and severe AD cases (Figure 4 Figure 5K ). In addition, spheroids of twisted Rac1b-positive filaments were also seen in the region of the NB ( Figure 5L ). These different Rac1b-immunostained profiles were mainly observed in mild AD and severe AD and resembled the cytoskeletal abnormalities described within the NB with the use of the pretangle marker AT8 during NFT formation. 23 Rac1b-positive cells with an NFT-like profile as well as neuropil threads and dystrophic neurites (data not shown) were also seen in the cortex of mild and severe AD cases ( Figure 5G ) but not in NCI or MCI cortex (data not shown). Pre-absorption with the Rac1b protein did not block immunoreactivity for AT8 or Alz50-ir within the NB ( Figure 5, M and N) , suggesting that these tau antibodies did not cross-react with Rac1b. In the other tauopathies examined, only two LBD ( Figure 5O ) and two FTD ( Figure  5P ) cases showed dual immunostaining for p75 NTR and Rac1b in NB neurons (Table 2 ).
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Dual Labeling for Rac1b and Tau Immunoreactivity within NB Neurons
To evaluate whether Rac1b profiles co-expressed different tau isoforms in NB neurons during the course of AD, immunofluorescence staining of Rac1b and selected tau epitopes was performed with the use of tissue from each of the groups examined in this study ( Figure 6 , A-I). Virtually all Rac1b neurons colocalized with AT8, AT180, and Alz50 immunoreactivity in the NB during AD progression ( Figure 6 , A-I). However, only an occasional single Rac1b-ir neuron was observed in AD ( Figure 6 , C and I). Rac1b-ir neurons expressing Alz50 and AT8 were seen more often in MCI and AD ( Figure 6 , B, C, E, and F) than NTR -labeled neurons from NCI. Although relatively few genes displayed alterations across the individual cell types, significant differences were found in the expression levels for mRNAs encoding the G protein ␤ polypeptide 4 (GNB4), fetal Alzheimer antigen (FALZ), lipase A (LIPA), and caveolin 2 (CAV2) genes (Figure 8 ; see also Supplemental Table S1 at http://ajp.amjpathol. org). Specifically, FALZ levels were significantly reduced in AD p75 NTR compared with NCI p75 NTR -positive NB neurons but not within AD Rac1b ϩ /p75 NTR NB-labeled neurons (P Ͻ 0.05; Figure 8A ). By contrast, transcript levels of GNB4, LIPA, and CAV2 were significantly downregulated in AD Rac1b ϩ /p75 NTR -positive NB neurons compared with NCI p75 NTR -ir NB neurons (P Ͻ 0.05; Figure 8 , B-D). Moreover, CAV2 mRNA was reduced in AD Rac1b ϩ /p75 NTR -positive NB neurons compared with ADp75 NTR -positive NB neurons ( Figure 8D ; P Ͻ 0.05).
Discussion
Herein, we provide biochemical, genomic, and morphologic evidence that Rac1b, a constitutively active Rac1 splice variant, accumulates within cholinergic NB neurons during the progression of AD. Rac1b protein expression within a select group of p75 NTR -positive NB neurons is significantly increased in moderate and severe AD compared with MCI and NCI cases. These Rac1b/ p75 NTR -positive neurons displayed a phenotype comparable to the tau cytoskeletal abnormalities described during the progression of NFTs within the NB in AD. 23 Singlecell gene array analysis of Rac1b/p75
NTR dual-labeled NB neurons showed a decrease in GNB4, LIPA, and CAV2 transcripts in AD compared with singly labeled p75 NTR -containing neurons in NCI, suggesting that Rac1b activity regulates lipid metabolism and cell-cycle pathways (see below). Hence, these signaling cascades may be linked to Rac1b-mediated cytoskeletal and membrane dysfunction, resulting in NB NFT pathology and ultimately neuronal death in advanced AD.
The present study showed that Rac1b was selectively expressed in a subpopulation of p75 NTR -positive cholinergic neurons within the NB in AD. In this regard, the percentage of the double-labeled Rac1b ϩ /p75 NTR -ir NB neurons increased in mild and severe AD compared with MCI and NCI. Although the functional consequences of the expression of Rac1b within NB neurons remain unknown, studies suggest that it may interact with the CBF neuron survival factor NGF and its receptors. The differentiation, survival, and function of CBF neurons depend on the binding of NGF to its cognate receptor TrkA 77, 78 and the pan-neurotrophin receptor p75 NTR . 79 -81 These receptors are produced in CBF neurons and transported to their cortical projection sites. 81, 82 In general, the TrkA receptor is associated with cell survival, whereas p75 NTR shows a dichotomous role that induces cell survival or apoptosis, depending on the cellular milieu. Clinical pathologic studies show that the ratio of TrkA to p75 NTR receptors is decreased during the progression of AD, suggesting that the NGF system shifts from cell survival to cell death during disease onset. 83 Interestingly, reports indicate that p75 NTR -mediated apoptosis requires the activation of Rac1. 26, 84 Therefore, the increase in number of p75 NTR -positive NB neurons expressing Rac1b could be indicative of its involvement in p75 NTRmediated apoptotic signaling pathways within these cholinergic neurons in AD. Although the mechanism whereby Rac1b expression might promote neurodegeneration is unclear, it has been shown that Rac1b stimulates the 85 Indeed, NB neurons display a greater expression of cell cycle-related proteins such as cyclin D1 and proliferating cell nuclear antigen in MCI and AD compared with NCI. 86, 87 The presence of these proteins in NB as well as in cortical neurons has been interpreted as a lethal reentrance into the cell cycle that promotes an aberrant DNA replication that precedes cellular death. 86 Significantly, cell cycle kinases such as cdc2 have been shown to contribute to tau hyperphosphorylation, 88 suggesting a role for Rac1b in reactivating cell cycle progression that contributes to neurofibrillary degeneration in postmitotic neurons in AD. On the one hand, the expression of Rac1b in p75
NTR NB-positive neurons may stimulate anti-apoptotic signaling that, in turn, activates proteins associated with cell survival (such as Akt) similar to those described for Rac1. 34, 85 Whether Rac1b interacts with p75 NTR to promote cell death or survival during the course of AD is an area requiring continued investigation. On the other hand, the concept that intraneuronal p75 NTR is a necessary precondition for the induction of Rac1b is not supported by our observations that cortical neurons also display Rac1b but are p75 NTR immunonegative in AD. Several lines of evidence suggest that dysregulation of Rac1 GTPase activity plays a key role in cytoskeletal perturbations that lead to the formation of NFTs in AD, 6, 27, 28 particularly within CBF neurons. 26 In the present study, we observed that Rac1b colocalizes with markers of NFT formation within the NB cholinergic neurons mainly in the later stages of the disease. In addition, the morphologic appearance of Rac1b in NB neurons was similar to the cytoskeletal changes described with the AT8 antibody, suggesting that Rac1b participates in the induction of cytoskeletal alterations related to NFT formation in AD. Our double/triple labeling experiments showed that most of the Rac1b-positive neurons in the NB colocalized with either phosphorylation-dependent and/or conformational tau markers in AD and to a lesser extent in MCI. We also found Rac1b-ir cholinergic neurons with the NB in LBD and FTD cases, suggesting that the expression of Rac1b in NB cholinergic neurons is a common feature of tauopathies. Perhaps GTPase protein effectors engage mechanisms related to tau aggregation/NFT formation and other cytoskeletal-related inclusions such as the FTD fused in sarcoma protein.
Another contributing factor to the putative effects of Rac1b on NFT formation may be its interactions with A␤, which is thought to be a prime agent in the pathogenesis of AD, 89 including NFT formation. 90 -92 In this regard, we have found that A␤ stimulates Rac1b recruitment in neurons (unpublished observations, Desire 2008). Moreover, in the present study we reported that Rac1b-positive neurons, in areas of the cortex, contain A␤ pathology in mild and severe AD cases. In vivo and in vitro studies have shown that A␤ modifies Rac1 activity, causing changes in filamentous actin cytoskeletal dynamics. 27, 28 Moreover, abnormal accumulation of filamentous actin has been associated with tau-induced neurodegeneration in mouse models of tauopathy. 93 Although, virtually no extracellular or intracellular A␤ is present in the region containing the NB, 94 we cannot exclude the possibility that cortical A␤ might induce a retrograde signal, which activates either Rac1 or Rac1b, resulting in cytoskeletal alterations underlying NFT formation within CBF neurons.
The present single-cell gene expression profiling experiments showed specific Rac1b-dependent reductions in genes relevant to cell cycle re-entry (GNB4) and lipid metabolism (CAV2 and LIPA) in AD p75 NTR -positive NB neurons compared with NCI p75 NTR -ir NB neurons. This gene signature provides a fairly unique expression profile that has not been observed by our group in other types of neurons in the NB or in hippocampal tangle-bearing neurons in AD. 41, 66, 75 Because we also found Rac1b-positive neurons in the AD cortex, it will be interesting to determine whether these perikarya display a similar gene profile to that found in the NB cholinergic neurons. GNB4 is a transducer of membrane receptor signaling related to cell cycle. CAV2 is found in membrane lipid rafts and plays a role in membrane fluidity, protein trafficking, neurotransmission, and receptor trafficking. 95 Dysfunction in lipid rafts occurs in normal aging and AD 95, 96 and may play a key role in the synthesis of A␤ and its oligomerization in AD. 97 Although the relationship between CAV2 and Rac1b remains unknown, we speculate that CAV2 plays a role in the regulation of Rac1b in AD. Future studies will be necessary to determine the role and relationship between caveolin proteins and Rac in AD. Likewise, there was a reduction in LIPA transcript levels in AD Rac1b ϩ /p75 NTR compared with NCI p75 NTR -positive NB neurons. This enzyme, which is found in lysosomal membrane compartments, breaks down lipids such as cholesteryl esters and triglycerides, and mutations in LIPA result in cholesteryl ester storage diseases, such as Wolman disease. Taken together, these data suggest that Rac1b activity involves molecular interactions with pathways that regulate lipid metabolism/plasma membrane maintenance, which potentially contribute to the pathophysiology seen in AD. 98 In summary, our study shows biochemical, genomic, and morphologic evidence that Rac1b, a constitutively active Rac1 spliced variant, increases in a subpopulation of p75 NTR -positive NB neurons that colocalize with pathologic tau epitopes during the course of AD. Likewise Rac1b ϩ /p75 NTR -positive neurons display a significant down-regulation of GNB4, LIPA, and CAV2 mRNAs in severe AD. Overall, the present data suggest that increased Rac1b expression acts as a modulator or transducer of various signaling pathways, including cell-cycle re-entry and lipid metabolism that leads to NFT formation and membrane dysfunction in a subgroup of p75 NTR cholinergic NB neurons in AD. Perhaps, Rac1b inhibitors may be useful to study the function of this splice variant in AD. 33 
